SH-110

Disease state overview

SH-110 capsules are the standard of care for the treatment of Glioma:

• 12,731 adult patients in the US are diagnosed per year¹
• 2,021 pediatric patients in the US are diagnosed per year¹
• Glioma is an orphan disease

Regulatory Status

Shorla Oncology have completed a successful pre-IND meeting with the US Health Authority, the Food and Drug Administration (‘FDA’) on our third oncology drug SH-110. This proprietary product will have a significant benefit to patients suffering from brain cancer ultimately reducing treatment burden and providing a palatable age appropriate treatment. With this positive outcome we will progress our development programme for this much needed drug.

¹National Brain Tumor Society Facts.